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Poster Session II 129Chronic graft-versus-host disease (CGVHD) is more frequent
following peripheral blood stem cell (PBSCT) than bone marrow
transplantation (BMT). However, the responsiveness of the disease
to immune-suppression using either stem cell source has not been
well validated. We compared the time to discontinuation of im-
mune-suppression between PBSCT and BMT in 184 patients
with CGVHD after sibling donor transplantation. Of 717 sibling
donor transplants (1990–2004), the cumulative incidence of
CGVHD was 25% (95% CI 22–28%) overall and was more fre-
quent after PBSCT [39% (95% CI 32–46%) versus BMT 17%
(95% CI 14–20%), p \ 0.01]. The incidence of discontinuation
of immune-suppression (DIS) was 9% (95% CI 5–13%) at 1 year,
and 67% (95% CI 52–82%) by 5 years [DIS at 1 year: BMT 15%
(95% CI 7–23%) versus PBSCT 5% (95% CI 1–9%); and at 2 years:
38% (95% CI 26–50%) versus 32% (95% CI 22–42%); however
both approached 67% by 5 years]. The multivariate analysis was re-
stricted to adult patients who received myeloablative conditioning
(n5 130, 63 BMT, 67 PBSCT) due to interaction between pediatric
age group and stem cell source (17/19 pediatric patients received
BMT); and conditioning regimen and stem cell source (35/37 re-
ceiving non myeloablative conditioning regimen also received
a PBSCT). PBSC recipients, those with progressive onset of
CGVHD and thrombocytopenia (\100,000/ml) at diagnosis of
CGVHD had lower rates of DIS than BM recipients (Table). After
a median follow-up of 33 months, a trend towards superior overall
survival at 5 years was seen in the BMT cohort [5 year survival:
BMT 65% (95% CI 53–75%) versus PBSCT 58% (95% CI 45–
69%) p5 0.07]. Following sibling donor transplantation, CGVHD
is more frequent and more resistant to immune-suppressive therapy
using PBSC vs. BM. PBSC recipients were significantly more likely
to require prolonged immune-suppression and extended morbidity
from CGVHD. Careful attention to this serious later morbidity and
mortality should guide clinical decisions about the use of either BM
or PBSC sources for sibling donor transplantation.
Time to Hazard Ratio (95% C.I.)
Discontinuation of
Immune Suppression
(.1 5more frequent/
quicker DIS) PStem Cell Source
Marrow 1.0 \0.01
PBSC 0.5 (0.3–0.8)
Onset of CGVHD
Quiescent/Denovo 1.0 0.01
Progressive 0.5 (0.3–0.7)No. of Organs involved
with GVHD
1 1.0
2 0.8 (0.4–1.4) 0.29
31 0.7 (0.3–1.3) 0.21Thrombocytopenia
\100,000/mL 1.0 \0.01
$100,000/mL 2.0 (1.3–3.3)Overall Survival [Kaplan-Meier estimate (95% CI)], p 5 0.07
Marrow PBSCAt 2 years 77% (66–84%) 70% (60–78%)
At 5 years 65% (53–75%) 58% (45–69%)352
EFFICIENT AND SELECTIVE PREVENTION OF GRAFT-VERSUS-HOST DIS-
EASE BY ANTIGEN-SPECIFIC TGFb-INDUCED REGULATORY T CELLS
Yu, X.-Z.1,2, Iclozan, C.1, Anasetti, C.1,2. 1H. LeeMoffitt Cancer Center
& Research Institute, Tampa, FL; 2University of South Florida, Tampa,
FL.
Naturally occurring regulatory T cells (nTregs) suppress the
development of graft-versus-host disease and may spare graft-ver-
sus-tumor effect. As nTreg is a rare cell population in a healthy in-
dividual, using in vitro expanded nTregs is a common strategy to test
their therapeutic potential in hematopoietic cell transplantation
(HCT). However, the concern of in vitro expanded nTregs may in-clude their stability of Foxp3 expression and suppressive function,
survival in vivo, and non-selective suppression of pre-activated
nTregs. In this study, we have used an alternative strategy to gener-
ate antigen-specific, induced Tregs (iTregs). CD41CD25- cells
from OT-II TCR transgenic, foxp3/gfp knock-in mice were induced
to express Foxp3 by incubating with OVA peptide in the presence of
TGFb. CD41GFP1 cells were purified by sorting and used as
iTregs while CD41GFP- cells as controls. Their ability to prevent
GVHD was tested in a lethally irradiated murine BMT model: B6
/ (B6  bm12)F1. In order to evaluate the specificity of iTregs,
OVA-expressing or non-expressing (B6  bm12)F1 recipients
were compared side by side. We found that iTregs (CD41GFP1)
completely prevented GVHD lethality in OVA1 recipients at
a Treg:Teff ratio of 1:5. The efficacy of these antigen-specific iTregs
were significantly higher than polyclonal nTregs from B6 donors as
they could only partially prevent GVHD and prolong recipient sur-
vival even at a 1:1 ratio. In contrast, iTregs failed to prevent GVHD
in OVA- recipients. As controls, CD41GFP- cells had no effect on
GVHD development in OVA- recipients, and even exacerbated
GVHD in OVA1 recipients compared to B6 CD41 effector cells
alone. These results reveal the therapeutic potential of antigen-spe-
cific iTregs to prevent GVHD efficiently and selectively.353
GENERATION OF TREG-LIKE CELLS FROM CD41CD25- T CELLS VIA EPI-
GENETIC MODIFICATION USING A DEMETHYLATING AGENT DECITA-
BINE
Choi, J., Ritchey, J., DiPersio, J.F. Washington University in St. Louis,
School of Medicine, St. Louis, MO.
Naturally-occurring regulatory T cells (nTreg) contribute to the
maintenance of self-tolerance and have been reported to suppress
autoimmunity and GvHD in mouse models. Major obstacles for
their routine use in human clinical trials include the low number
of Treg, low efficiencies of purification and severe limitations in
ex vivo expansion without downregulating the expression of Foxp3
that is the master gene of Treg. Recent identification of demethy-
lated CpG islands within the Foxp3 locus only in Treg lead us to in-
vestigate whether an FDA-approved demethylating agent,
Decitabine, could be used to enhance expression of Foxp3 via an
epigenetic effect and convert CD41CD25- T cells into Treg. We
incubated human CD41CD25-FOXP3- T cells with anti-CD3/
CD28 beads and hIL-2, followed by Decitabine treatment. Real
time RT-PCR demonstrated levels of mRNA for FOXP3 that
were comparable to that seen in bead-activated nTreg. This resulted
in increased expression at the protein level in 60% of treated cells.
Decitabine also induced Foxp3 expression in 80% of murine
CD41CD25- T cells incubated with anti-CD3/CD28 beads and
hIL-2, followed by Decitabine treatment. The upregulation of
Foxp3 by Decitabine treatment was further validated with GFP ex-
pression in CD41CD25- T cells from Foxp3-ires-GFP KI mice.
The CD41CD25- T cells expanded approximately two fold com-
parable to 13–20 fold of the number of naı¨ve nTreg. These Decita-
bine-treated CD41CD25- T cells (dcT) showed suppressor
function in MLR. We next tested whether these cells were able to
suppress GvHD in an allogeneic BMT model. Mice that were trans-
planted with dcT showed significantly higher survival rate and
maintained their weight better. The Treg surface markers, such as
GITR, CTLA4, and CD25 were upregulated in the dcT. We also
found that GzmA and GzmB were upregulated. Using Prf 1 KO
and GzmB KO mice, we found that the suppressor function of
the dcT is partially dependent on Prf 1, but not on GzmB. A
transwell experiment demonstrated that the suppressor function
of dcT is cell-contact dependent. The gene expression profiles
were also compared between dcT, naı¨ve nTreg, and bead-activated
nTreg. We found that dcT expressed high level of CTLA-4,
GITR, CD25, and FR4, which have been known to be upregulated
in nTreg. In summary, Decitabine-treatment of CD41CD25- T
cells enhanced Foxp3 expression. These dcT showed suppressor
function in both in vitro and in vivo and shared part of gene signature
of nTreg.
